Introduction: Conventional radiotherapy or chemotherapy is
ineffective in the treatment of recurrent
and metastatic cervical cancer. In recent years, immunotherapy has shown
promise in the treatment of various solid tumours,
including cervical cancer. The overall response rate of the PD-1/PD-L1 inhibitor in cervical cancer is 14% -27%, and when combined with radiotherapy or conventional chemotherapy, the overall response
rate can be further improved.Case presentation: We report here a
case of a 49-year-old female patient presenting with two metastatic lesions of
cervical cancer after postoperative radiotherapy, the first was located in the
para-aortic region and the second in the presacral region. The enlarged
para-aortic lymph nodes had not previously
received radiotherapy, while the enlarged presacral lymph nodes had previously
received postoperative radiotherapy. Treatment results showed that the
recurrent presacral mass did not respond to the PD-1 inhibitor (camrelizumab) alone,
whereas the metastatic para-aortic lymph nodes responded favourably to
camrelizumab combined with low-intensity radiotherapy.Conclusion: PD1/PD-L1 inhibitors combined with radiotherapy
should make it possible to overcome the bottleneck of conventional
radiotherapy, improve patient prognosis or achieve
References
[1]
Puspitasari, I.M., Legianawati, D., Sinuraya, R.K., et al. (2021) Cost-Effectiveness Analysis of Chemoradiation and Radiotherapy Treatment for Stage IIB and IIIB Cervical Cancer Patients. International Journal of Women’s Health, 13, 221-229.
https://doi.org/10.2147/IJWH.S289781
[2]
Chung, H.C., Ros, W., Delord, J.P., et al. (2019) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 37, 1470-1478.
https://doi.org/10.1200/JCO.18.01265
[3]
Wang, Y.M. and Li, G.L. (2019) PD-1/PD-L1 Blockade in Cervical Cancer: Current Studies and Perspectives. Frontiers of Medicine, 13, 438-450.
https://doi.org/10.1007/s11684-018-0674-4
[4]
Keita, M., Xi, C., Bah, M., Diallo, F.B., Fang, Z., et al. (2022) The Impact of Prophylactic Para-aortic Lymph Nodes Radiotherapy in Small Cell Carcinoma of the Cervix: A Case Report and Literature Review. Journal of Oncology Research and Treatment, 7, Article No. 4.
[5]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[6]
Dong, H.D., Strome, S.E., Salomao, D.R., et al. (2002) Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. Nature Medicine, 8, 793-800. https://doi.org/10.1038/nm730
[7]
Zheng, S., Lu, J.J., Liu, Y.H., et al. (2020) Synergistic Antitumor Effect on Cervical Cancer by Rational Combination of PD1 Blockade and CRISPR-Cas9-Mediated HPV Knockout. Cancer Gene Therapy, 27, 168-178.
https://doi.org/10.1038/s41417-019-0131-9
[8]
Kim, H.S., Kim, T., Lee, E.S., et al. (2013) Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic Metastasis. Cancer Research and Treatment, 45, 193-201. https://doi.org/10.4143/crt.2013.45.3.193
[9]
Liu, Y., Wu, L., Tong, R., et al. (2019) PD-1/PD-L1 Inhibitors in Cervical Cancer. Frontiers in Pharmacology, 10, Article No. 65.
https://doi.org/10.3389/fphar.2019.00065
[10]
Antonia, S.J., Villegas, A., Daniel, D., et al. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. The New England Journal of Medicine, 379, 2342-2350. https://doi.org/10.1056/NEJMoa1809697
[11]
Kasmann, L., Taugner, J. and Manapov, F. (2019) Chemo-/Immuno-/Radiotherapy Combination in Treatment of Solid Cancer. Oncotarget, 10, 5387-5388.
https://doi.org/10.18632/oncotarget.27141